Clinical trial using focused ultrasound with chemotherapy finds potential survival benefit for brain cancer patients

The multicenter trial, led by researchers at the University of Maryland School of Medicine, found a nearly 40 percent increase in overall survival when focused ultrasound was used to temporarily open the blood-brain barrier during standard-of-care chemo

2025-11-25

(Press-News.org) Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40 percent increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers. This is the first time researchers have demonstrated a potential survival benefit from using focused ultrasound to open the blood-brain barrier to improve delivery of chemotherapy to the tumor site in brain cancer patients after surgery.

“Our results are very encouraging. Using focused ultrasound to open the blood-brain barrier and deliver chemotherapy could significantly increase patient survival, which other ongoing studies are seeking to confirm and expand,” said study principal investigator Graeme Woodworth, MD, Professor and Chair of Neurosurgery at UMSOM and Neurosurgeon-In-Chief at the University of Maryland Medical Center (UMMC).

Click here to view photos and videos related to this publication.

The findings of this groundbreaking safety, feasibility, and comparative trial involved glioblastoma patients who were given focused ultrasound to open their blood-brain barrier before getting chemotherapy; they were matched to a rigorously selected control group of 185 glioblastoma patients with similar characteristics who received the standard dose of the chemotherapy drug, temozolomide, without receiving focused ultrasound. Trial participants were initially treated with surgery to remove their brain tumor, followed by six weeks of chemotherapy and radiation, and up to six monthly focused-ultrasound treatments plus temozolomide.

Results were published in the journal Lancet Oncology and show that trial participants had nearly 14 months of median progression-free survival, compared to eight months in the control group. In terms of overall survival, trial participants, on average, lived for more than 30 months compared to 19 months in the control group.

The study builds on more than a decade of intensive research to test the safety and feasibility of opening the blood-brain barrier using focused ultrasound first in animal studies and then in patients. It was led by Dr. Woodworth and was conducted at UMMC and four other clinical sites affiliated with the University of Toronto, Harvard University, University of Virginia, and West Virginia University. “We also demonstrated that this could be a useful technique that enables us to better monitor patients to determine if their brain cancer has progressed,” said Dr. Woodworth, who also serves as Director of the Brain Tumor Program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

He and his team demonstrated that opening the blood-brain barrier facilitated the use of a
“liquid biopsy,” which is a blood test that detects cancer biomarkers, which can include DNA fragments, proteins and other components from the liquid environment surrounding the tumor site.

Such biomarkers have been used in other cancers to determine whether the tumor has remained stable or has the potential to progress or even metastasize. Up until now, however, these tests have not been utilized in brain cancer patients since most components can never pass into the bloodstream from the brain due to the blood-brain barrier.
“These liquid biomarkers were found to be closely concordant with the patient outcomes over time, progression-free survival and overall survival,” said Dr. Woodworth.

While temozolomide is the standard treatment for glioblastoma, the drug typically gets blocked by the blood-brain barrier with studies showing that less than 20 percent reaches the brain in patients. This study did not determine the exact amount of temozolomide to reach the brain in each patient, but earlier studies have shown that opening the blood-brain barrier before delivering chemotherapy can dramatically increase the amount that gets to the original tumor site.

Glioblastoma is the most common and deadliest type of malignant brain tumor. The five-year survival rate is only 5.5 percent, and patients live an average of 14 to 16 months after diagnosis when treated with surgery, radiation, and chemotherapy when appropriate. The malignancy nearly always recurs even after it is removed due to residual infiltrating cancer cells that remain after treatment.

The blood-brain barrier is a specialized network of vascular and brain cells that acts as the brain’s security system to protect against invasion by dangerous toxins and microbes. It can be opened temporarily using a specialized focused ultrasound device. This process starts with injecting microscopic inert gas-filled bubbles into the patient’s bloodstream. Guided by an MRI, precise brain regions are targeted while the injected microbubbles are circulating.

“Upon excitation under low-intensity ultrasound waves, the microbubbles oscillate within the energy field, causing temporary mechanical perturbations in the walls of the brain blood vessels,” said Pavlos Anastasiadis, PhD, an Assistant Professor of Neurosurgery at UMSOM who is an expert in ultrasound biophysics.

Prior studies led by Dr. Woodworth and this trial’s co-investigators showed that opening the blood-brain barrier temporarily can be safely and feasibly performed in brain tumor patients. He and his team conducted this procedure in the first brain cancer patient in the U.S. in 2018 at UMMC after the US Food and Drug Administration (FDA) approved the inaugural clinical trial.

“Dr. Woodworth’s findings are deeply exciting and a significant step forward for the field,” said Taofeek K. Owonikoko, MD, PhD, UMGCCC Executive Director. “Patients with glioblastoma have had few effective treatment options, and UMGCCC is proud to be at the forefront of efforts to bring hope to these patients and their families.”

Future trials could use focused ultrasound alongside other chemotherapy agents to test the effectiveness of drugs never used in brain cancer due to their ineffectiveness at crossing the blood-brain barrier.

“This groundbreaking trial has provided a potential new prognostic and therapeutic paradigm for the 15,000 Americans who are diagnosed every year with this deadly form of brain cancer,” said UMSOM Dean Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Vice President for Medical Affairs at University of Maryland, Baltimore. “The release of biomarkers into the bloodstream offers a possible new method for simple and routine monitoring of brain regions without the need for invasive biopsies. Having the ability to open the blood-brain barrier could also usher in the testing of new therapeutics to see whether they offer further life-extending benefits.”

"For the thousands of people who receive this devastating diagnosis each year, the significance of this advancement cannot be overstated," said Bert W. O'Malley, MD, President and CEO of UMMC. "The success of this trial brings new momentum and further accelerates investigation of targeted therapies for glioblastoma and other brain cancers. Hope has been redefined for these families.”

Dr. Woodworth is also the co-leader of a larger diagnostics-focused pivotal focused ultrasound trial in glioblastoma patients called LIBERATE (NCT05383872) in partnership with ReFOCUSED (The Research Consortium for Transcranial Focused UltraSound-Enhanced Drug Delivery & Diagnostics.) ReFOCUSED is a growing group of researchers from over 20 sites across North America whose goal is to use the new opportunities offered by MRI-guided focused ultrasound to improve the clinical outcomes of brain diseases. The LIBERATE trial is currently closed to enrollment.

This trial was funded by the device manufacturer Insightec Inc. (Miami, FL), an MRI-guided focused ultrasound device company, and the National Institutes of Health (NIH) (R21NS113016).

About the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is a National Cancer Institute-designated comprehensive cancer center within the University of Maryland Medical Center in Baltimore, the flagship academic hospital of the University of Maryland Medical System. It offers a multidisciplinary approach to treating all types of cancer and has an active clinical and basic science research program through its relationship with the University of Maryland School of Medicine. The center is ranked among the top 50 cancer programs in the country by US News & World Report. www.umgccc.org

END

ELSE PRESS RELEASES FROM THIS DATE:

World-first platform for transparent, fair and equitable use of AI in healthcare

2025-11-25

Researchers have developed the world’s first real-world head-to-head testing platform to determine whether commercial artificial intelligence (AI) algorithms are fit for NHS use to detect disease in a fair, equitable, transparent and trustworthy way, using diabetic eye disease as the first example. They say that it removes any biases that can come from companies wanting to deploy their AI software in clinical settings, putting all companies on a level playing field. Currently, NHS AI algorithm selection focuses on cost-effectiveness and matching human performance. ...

New guideline standardizes outpatient care for adults recovering from traumatic brain injury

2025-11-24

Special Report Traumatic brain injury (TBI) affects millions of Americans each year and can result in long-lasting symptoms. Previously, outpatient TBI care lacked standardized guidance that could not apply uniformly to adults with TBI who could care for themselves after hospital discharge or who did not require hospital admission. The National Academies’ 2022 report on TBI identified this gap and called for coordinated follow-up care, leading to the formation of the Action Collaborative on TBI Care. The collaborative’s Clinical Practice Guideline Working Group synthesized and adapted recommendations from 18 existing evidence-based guidelines ...

Physician shortage in rural areas of the US worsened since 2017

2025-11-24

The national shortage of primary care physicians has been a concern for years, and a new study in the Annals of Family Medicine underscores how urgent the problem is and where the biggest pain point lies: in rural parts of the country that are seeing the largest population spikes in nearly a century. By studying the location of practicing family physicians across the U.S. from 2017 to 2023, authors found a year-over-year decrease in family physicians practicing in rural areas, with a net loss of 11% nationwide over the 7 years studied. The greatest losses were in the Northeast and fewest in the West. There were 11,847 ...

Clinicians’ lack of adoption knowledge interferes with adoptees’ patient-clinician relationship

2025-11-24

Original Research Background: Researchers examined health care challenges faced by adult adoptees and how being adopted affects relationships with their clinicians. U.S. adult adoptees completed a mixed-methods online survey. A total of 204 participants were included in the final analysis. What This Study Found: Most participants described multiple types of adoption-related bias by clinicians: More than half of the participants reported clinicians made insensitive or inaccurate statements related to adoption (68%), ignored or dismissed adoption-related concerns (60%), or made them feel uncomfortable, unwelcome, or unsupported ...

Tip sheet and summaries Annals of Family Medicine November/December 2025

2025-11-24

Original Research Older Adults Who See the Same Primary Care Physician Have Fewer Preventable Hospitalizations Background: Continuity of care has been linked with fewer hospitalizations. This study examined whether better continuity is helpful for acute, potentially preventable hospitalizations that might be avoided with regular care. Researchers analyzed data for 54,376 adults aged 45 years and older from the long-term “45 and Up Study” in New South Wales, Australia. Survey responses were linked with Medicare general practitioner claims and hospital admission ...

General practitioners say trust in patients deepens over time

2025-11-24

Original Research Background: In this study, researchers aimed to understand how general practitioners experience trust in their patients, and how that trust affects patient care. Researchers interviewed 25 general practitioners across Australia. What This Study Found: Interviewees ranged from 28 to 65 years old. Three themes described general practitioners’ trust in patients: General practitioners’ trust in patients was an assumed starting point. General practitioners expressed a lack of trust in some complex ...

Older adults who see the same primary care physician have fewer preventable hospitalizations

2025-11-24

Original Research Background: Continuity of care has been linked with fewer hospitalizations. This study examined whether better continuity is helpful for acute, potentially preventable hospitalizations that might be avoided with regular care. Researchers analyzed data for 54,376 adults aged 45 years and older from the long-term “45 and Up Study” in New South Wales, Australia. Survey responses were linked with Medicare general practitioner claims and hospital admission records from 2007 to 2017. Researchers used a double machine learning approach to separate the effect of continuity of care from the ...

Young European family doctors show moderate readiness for artificial intelligence but knowledge gaps limit AI use

2025-11-24

Research Brief Background: In this study, researchers surveyed 134 young family physicians from 20 European countries to understand how ready they are to use AI in primary care. The web survey used the Medical AI Readiness Scale (MAIRS), which rates four areas: cognition (understanding), ability (skills), vision (future value), and ethics. The maximum possible score is 110, with higher scores indicating greater readiness. What This Study Found: Overall readiness was moderate (median 69/110) with wide variation. About one-quarter of participants said they never use AI in family medicine, ...

New report presents recommendations to strengthen primary care for Latino patients with chronic conditions

2025-11-24

Special Report Latinos face significant health disparities, especially in chronic conditions such as cardiovascular disease, diabetes, asthma, and cancer. Primary care clinicians play a critical role in managing and preventing these diseases, yet Latinos face multiple barriers to quality care. In April 2024, the Primary Care Latino Equity Research (PRIMER) Center convened the Latino Primary Care Summit on “Chronic Conditions in Latinos: Trends, Innovations and Care for the Future.” This special report summarizes the discussions at the summit and ...

Study finds nationwide decline in rural family physicians

2025-11-24

Research Brief Background: In this study, researchers used the American Medical Association Physician Masterfile to identify family physicians aged 65 years or younger in the U.S. actively practicing outpatient care from 2017 to 2023. Physicians’ office addresses were mapped to the U.S. Department of Agriculture’s Rural-Urban Continuum Codes to identify and describe family physicians in rural communities. What This Study Found: There has been an 11% nationwide decline in rural family physicians from 2017 to 2023. The Northeast saw the greatest percentage loss (15.3%), while the West saw the least (3.2%). The proportion ...

LAST 30 PRESS RELEASES:

Genetic study links impulsive decision making to a wide range of health and psychiatric risks